RxDoctor Payments Data

Ryan Crouch, DO

Internal Medicine · Grand Island, NENPI 1790724201

Payments from drug & device makers

$2,060in general payments, 2019–2025

Across 106 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$286
  • Johnson & Johnson$264
  • Siemens Medical Solutions USA, Inc.$184
  • Mallinckrodt Hospital Products Inc.$123
  • Pfizer$114
  • Amgen$80
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$2,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,060 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$238,610
Medicare patients
498
Services billed
5,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$112,642
OzempicSemaglutide116$107,876
JardianceEmpagliflozin108$92,687
XareltoRivaroxaban127$80,329
MounjaroTirzepatide60$64,039
FarxigaDapagliflozin Propanediol39$38,443
JanuviaSitagliptin Phosphate42$35,492
TrulicityDulaglutide24$22,676
MyrbetriqMirabegron36$20,794
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$18,321
RexultiBrexpiprazole22$17,770
Combivent RespimatIpratropium/Albuterol Sulfate25$12,200
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$11,468
Potassium Chloride445$11,016
EntrestoSacubitril/Valsartan30$10,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$112,642152 claims
Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi$32$112,231145 claims
Novo NordiskOzempic$28$107,876116 claims
Lilly USA, LLCMounjaro, Trulicity$59$86,71484 claims
Johnson & JohnsonXarelto$264$80,329127 claims
AstraZenecaFarxiga$286$38,44339 claims
MerckJanuvia$13$35,49242 claims
Astellas Pharma US IncMyrbetriq$57$20,79436 claims
GSKTrelegy Ellipta$24$18,32131 claims
Otsuka America Pharmaceutical, Inc.Rexulti$16$17,77022 claims
AbbVieLinzess, Synthroid$30$12,85870 claims
NovartisEntresto$61$10,50430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →